Vpx Helps HIV-1 Infect Dendritic Cells Even When They Are Defended by Interferon
Author Information
Author(s): Thomas Pertel, Christian Reinhard, Jeremy Luban
Primary Institution: University of Geneva
Hypothesis
Can Vpx rescue HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon?
Conclusion
Vpx can significantly enhance HIV-1 transduction in dendritic cells that have been treated with type 1 interferon.
Supporting Evidence
- Vpx can increase HIV-1 transduction efficiency by up to 1,000-fold.
- Vpx does not affect the production of interferon or the expression of immune markers in dendritic cells.
- Vpx's effect is specific to HIV-1 and does not extend to HIV-2 or SIVMAC.
Takeaway
Vpx is like a superhero for HIV-1, helping it get into special immune cells even when those cells are trying to fight it off.
Methodology
The study involved treating human monocyte-derived dendritic cells with type 1 interferon and then challenging them with HIV-1 in the presence of SIVMAC VLPs.
Limitations
The study primarily focused on dendritic cells and may not be generalizable to other cell types.
Participant Demographics
Human blood donors were used to generate dendritic cells.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website